Document Detail

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
MedLine Citation:
PMID:  17704995     Owner:  NLM     Status:  MEDLINE    
The aim of our study was to examine compliance with a daily dose of 5 mg alendronate (ALN) and 2.5 mg risedronate (RDN) in actual practice, and to determine the causes of noncompliance through a questionnaire. In addition, we studied the quality of life (QOL) of patients through another disease-related questionnaire. The overall compliance rate remained at approximately 40% one year after the initial dose. The rates did not differ significantly between the ALN group (783 patients) and the RDN group (491 patients). The compliances in the female group and the rheumatism group were better than in the male group and the nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed adverse effects (AEs), and the other noncompliant patients stopped the medication in spite of having no AEs. A logistic regression analysis of factors that might have affected long-term compliance included AEs, an understanding of the disease, the method of ingestion, visiting medical facilities, the shape of the tablet, the cost of the drug, and the explanation of the doctor or pharmacist. This analysis showed that noncompliance occurred mainly due to AEs, the inconvenience of visiting a medical facility, unusual methods of ingestion, and a poor understanding of the disease. According to the results of the questionnaire for QOL assessment, the patients who continued the medication for more than 1 year had improved scores for pain in both the ALN and RDN groups. Osteoporotic treatment needs long-term patient compliance. To improve compliance, it is very important that doctors and pharmacists ensure that patients understand the purpose of this therapy.
Masayuki Kamatari; Shiro Koto; Nobuhiro Ozawa; Chie Urao; Yumiko Suzuki; Eri Akasaka; Kae Yanagimoto; Kazumi Sakota
Related Documents :
24374425 - Using mixed methods to examine the role of veterans' illness perceptions on depression ...
23579335 - Is low-level laser therapy in relieving neck pain effective? systematic review and meta...
24046285 - Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, me...
23480315 - The clinical relevance of self-reported premenstrual worsening of depressive symptoms i...
24798725 - Towards a personalized treatment in depression: endocannabinoids, inflammation and stre...
19714725 - Characterization of patients discharged from inpatient treatment for burnout: use of ps...
Publication Detail:
Type:  Journal Article     Date:  2007-08-25
Journal Detail:
Title:  Journal of bone and mineral metabolism     Volume:  25     ISSN:  0914-8779     ISO Abbreviation:  J. Bone Miner. Metab.     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-20     Completed Date:  2007-10-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9436705     Medline TA:  J Bone Miner Metab     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  302-9     Citation Subset:  IM    
Maruzen Pharmacy, 3-3-23-104 Nishimikuni, Yodogawa-ku, Osaka 532-0006, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alendronate / administration & dosage,  therapeutic use
Diphosphonates / administration & dosage,  therapeutic use*
Etidronic Acid / administration & dosage,  analogs & derivatives,  therapeutic use
Logistic Models
Osteoporosis / drug therapy*,  pathology
Patient Compliance / statistics & numerical data*
Quality of Life
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Diphosphonates; 105462-24-6/risedronic acid; 2809-21-4/Etidronic Acid; 66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabet...
Next Document:  Association analysis of the polymorphisms of the VDR gene with bone mineral density and the occurren...